SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023
October 05 2023 - 8:30AM
SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device
company developing proprietary solutions to reduce the consequences
of hyperinflammation on vital organs, announces that Eric Schlorff,
CEO, will present a company overview at the 8th Annual Dawson James
Small Cap Growth Conference on Thursday, October 12 at 2:30 p.m.
Eastern time (11:30 a.m. Pacific time). The conference is being
held at the Wyndham Grand Harborside Hotel in Jupiter, Fla.
“We are excited to share two very recent
transformational regulatory development at this conference,” said
Eric Schlorff, SeaStar Medical CEO. “The FDA has informed us to
expect an Approvable Letter within a month for use of our Selective
Cytopheretic Device (SCD) Pediatric in critically ill children with
acute kidney injury and sepsis or septic conditions, providing us
with clear path toward the first market approval for our patented
cell-directed extracorporeal therapy. We also received Breakthrough
Device Designation for the SCD in cardiorenal syndrome, which is
among the additional indications in which we believe dysregulating
the immune processes could provide significant benefit.”
A live webcast of the conference presentation
will be available on the Events & Presentations page of the
Company's website. A replay of the webcast will be available for 90
days.
About SeaStar
MedicalSeaStar Medical is a medical technology
company that is redefining how extracorporeal therapies may reduce
the consequences of excessive inflammation on vital organs. SeaStar
Medical’s novel technologies rely on science and innovation to
provide life-saving solutions to critically ill patients. The
Company is developing and commercializing cell-directed
extracorporeal therapies that target the effector cells that drive
systemic inflammation, causing direct tissue damage and secreting a
range of pro-inflammatory cytokines that initiate and propagate
imbalanced immune responses. For more information visit
https://seastarmedical.com/ or visit us on LinkedIn or Twitter.
Forward-Looking StatementsThis
press release contains certain forward-looking statements within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1955. These forward-looking
statements include, without limitation, SeaStar Medical’s
expectations with respect to the regulatory approval process for
HDE; the anticipated timing for commercialization of SCD; and the
benefits of SCD to treat acute kidney injury (AKI) and other
diseases. Words such as “believe,” “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,”
“will continue,” “will likely result,” and similar expressions are
intended to identify such forward-looking statements.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to
significant risks and uncertainties that could cause the actual
results to differ materially from the expected results. Most of
these factors are outside SeaStar Medical’s control and are
difficult to predict. Factors that may cause actual future events
to differ materially from the expected results include, but are not
limited to: (i) the risk that SeaStar Medical may not be able to
obtain regulatory approval of its SCD product candidates; (ii) the
risk that SeaStar Medical may not be able to raise sufficient
capital to fund its operations, including clinical trials; (iii)
the risk that SeaStar Medical and its current and future
collaborators are unable to successfully develop and commercialize
its products or services, or experience significant delays in doing
so, including failure to achieve approval of its products by
applicable federal and state regulators, (iv) the risk that SeaStar
Medical may never achieve or sustain profitability; (v) the risk
that SeaStar Medical may not be able to access funding under
existing agreements, including the equity line of credit and
forward purchase agreements; (vi) the risk that third-parties
suppliers and manufacturers are not able to fully and timely meet
their obligations, (vii) the risk of product liability or
regulatory lawsuits or proceedings relating to SeaStar Medical’s
products and services, (viii) the risk that SeaStar Medical is
unable to secure or protect its intellectual property, and (ix)
other risks and uncertainties indicated from time to time in
SeaStar Medical’s Annual Report on Form 10-K, including those under
the “Risk Factors” section therein and in SeaStar Medical’s other
filings with the SEC. The foregoing list of factors is not
exhaustive. Forward-looking statements speak only as of the date
they are made. Readers are cautioned not to put undue reliance on
forward-looking statements, and SeaStar Medical assume no
obligation and do not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contact:LHA Investor
RelationsJody Cain(310) 691-7100Jcain@lhai.com
# # #
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From Apr 2024 to May 2024
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From May 2023 to May 2024